Professor Phillip Darcy is an NHMRC Principal Research Fellow and Group Leader at the Peter MacCallum Cancer Centre. His work has been pivotal in developing novel T cell-based immunotherapy approaches for cancer patients. In particular, his studies involving the development of technology using gene‐modified T cells expressing chimeric antigen receptors (CARs) in preclinical models has led to licensing of an international patent to industry partners and underpins five FDA/TGA‐approved therapies for CD19+ blood cancers.

Professor Darcy’s work has also been integral in the first CAR T cell trial undertaken in Australia.